Evidence map›Paper›PMID 39080094›Full record

Observational studyArchives of dermatological research2024

Attentiveness and mental health in adolescents with moderate-to-severe atopic dermatitis without ADHD.

Amy S Paller, Mercedes E Gonzalez, Sarah Barnum, Judith Jaeger, Liyang Shao, Zafer E Ozturk, Andrew Korotzer

Registry-linked trialAbstract readObservational Study
In one paragraph

Observational study in Archives of dermatological research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05203380 (Neuropsychologic Assessments of Dupilumab-Treated Adolescents With Moderate-to-Severe Atopic Dermatitis), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05203380 completednot on this map

Neuropsychologic Assessments of Dupilumab-Treated Adolescents With Moderate-to-Severe Atopic Dermatitis

TypeobservationalSponsorRegeneron PharmaceuticalsRan2022 to 2023Enrolled45ConditionsModerate-to-severe Atopic DermatitisArmsdupilumab
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Amy S PallerNorthwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA. apaller@nm.org.
Mercedes E GonzalezPediatric Skin Research, Miami, FL, 33146, USA.
Sarah BarnumCognitionMetrics, LLC, Stamford, CT, 06903, USA.
Judith JaegerCognitionMetrics, LLC, Stamford, CT, 06903, USA.
Liyang ShaoRegeneron Pharmaceuticals Inc., Tarrytown, NY, 410591-6717, USA.
Zafer E OzturkSanofi, Cambridge, MA, 02142, USA.
Andrew KorotzerRegeneron Pharmaceuticals Inc., Tarrytown, NY, 410591-6717, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with moderate-to-severe atopic dermatitis (AD) experience intense chronic itch and impaired sleep. Reports from parents and teachers suggest that AD patients may also have attention problems. However, attention has not yet been directly assessed in AD patients. We utilized an objective, computer-based continuous performance test (CPT) validated for use in attention-deficit/hyperactivity disorder (ADHD) diagnosis to formally evaluate attention in adolescent AD subjects. This was a single-visit, cross-sectional, non-interventional study of moderate-to-severe (Investigator's Global Assessment [IGA] ≥ 3) AD subjects aged 12-17 years without clinician-diagnosed ADHD. Attention was evaluated using two performance-based measures: Conners, CPT-3 and the Stroop Color and Word Test. The primary parameter was CPT-3 detectability (d') measure. Lesional severity measures included Eczema Area and Severity Index (EASI) and body surface area (BSA) involvement. Subjects completed self-report rating scales assessing sensory responsiveness patterns (Adult/Adolescent Sensory Profile [AASP]), itch (Peak Pruritus Numerical Rating Scale [PP-NRS]), skin pain, quality of life, sleep, anxiety, and depressive symptoms. A total of 44 subjects were included in the study (61.4% female; mean age 15.0 [SD 1.78] years; mean EASI 20.4 [SD 7.8]; mean PP-NRS 7.0 [SD 1.8]). Results indicated substantial disease impact on sleep, quality of life, and comorbid anxiety and depressive symptoms. The mean (SD) Conners, CPT-3 d' T-score was 48.7 (SD 10.7), similar to the expected mean from a randomly selected age/gender-matched sample of the general population (50 [SD 10], by definition). Overall, 13.6% of subjects exhibited a d' T-score ≥ 60 (clinically significant poor performance), which was not greater than the expected general population value (15.9%). Subject-level data review by two psychologists determined that only 2 subjects demonstrated an overall response pattern that clearly indicated attention deficit. Many subjects had atypical sensory responsiveness profiles: sensory hypersensitivity (38.6%), sensory avoidance (50%), and low registration (hypo-sensitivity, 36.4%). Adolescents with moderate-to-severe AD without existing ADHD diagnosis did not demonstrate greater attention problems on performance-based measures than would be expected in age/gender-matched peers.Trial registration NCT05203380.

Indexed as

Dermatitis, AtopicMental HealthQuality of LifeAdolescentAnxietyAttentionAttention Deficit Disorder with HyperactivityChildCross-Sectional StudiesDepressionFemaleHumansMalePruritusSeverity of Illness IndexADHDAtopic dermatitisAttentionConners, Continuous Performance TestMental healthPruritus

Identifiers

PMID39080094
PMCPMC11288989

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.